872592-39-7

Upstream product

• 624734-30-1 (1S,3R)-3-((tert-butoxycarbonyl)amino)-1-isopropylcyclopentane-1-carboxylic acid 
• 15532-75-9 1-(3-Trifluoromethylphenyl)piperazine 
• 624734-32-3 (1S,4S)-4-[(tert-butoxycarbonyl)amino]-1-isopropylcyclopent-2-ene-1-carboxylic acid 

Downstream Products

• 872592-40-0 (1R,3S)-3-isopropyl-3-({4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}carbonyl)cyclopentanamine 
• 1287693-25-7 C₂₆H₃₈F₃N₃O₂ 
• 1287693-24-6 C₂₆H₃₈F₃N₃O₂ 
• 1287693-27-9 C₂₆H₃₈F₃N₃O₂ 
• 1287693-26-8 C₂₆H₃₈F₃N₃O₂ 
• 1287693-46-2 C₂₇H₄₀F₃N₃O₂ 
• 1287693-45-1 C₂₇H₄₀F₃N₃O₂ 
• 1287693-48-4 C₂₇H₄₀F₃N₃O₂ 
• 1287693-47-3 C₂₇H₄₀F₃N₃O₂ 

Relevant academic research and scientific papers

Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist

We report the discovery of a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist (3S,4S)-N-[(1R,3S)-3-isopropyl-3-({4-[4- (trifluoromethyl)pyridin-2-yl]piperazin-1-yl}carbonyl)cyclopentyl] -3-methoxytetrahydro-2H-pyran-4-amine (19). After evaluation in 28-day toxicology studies, compound 19 (INCB10820/PF-4178903) was selected as a clinical candidate.

3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS

The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.